Graft vs Host Disease

Latest News

Responses to Belumosudil Persist at 3 Years in Chronic GVHD
Responses to Belumosudil Persist at 3 Years in Chronic GVHD

May 7th 2024

Patients with chronic graft-vs-host disease treated with belumosudil experienced responses out to 3 years with no new safety signals.

Patient-Reported Symptoms via Mobile App May Help Expedite GVHD Identification, Treatment
Patient-Reported Symptoms via Mobile App May Help Expedite GVHD Identification, Treatment

April 26th 2024

Adding Azoles May Not Impact Efficacy of Ruxolitinib in Acute GVHD Treatment
Adding Azoles May Not Impact Efficacy of Ruxolitinib in Acute GVHD Treatment

February 27th 2024

Ruxolitinib Plus Belumosudil Confers a 55% Response Rate in GVHD
Ruxolitinib Plus Belumosudil Confers a 55% Response Rate in GVHD

February 26th 2024

Ruxolitinib Cream Improves Body Surface Area in Cutaneous GVHD
Ruxolitinib Cream Improves Body Surface Area in Cutaneous GVHD

February 24th 2024

Latest CME Events & Activities

Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma

View More

Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care

View More

Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

View More

Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer

View More

8th Annual School of Nursing Oncology™

August 10, 2024

Register Now!

Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease

View More

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

View More

The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…

View More

Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care

View More

More News

© 2024 MJH Life Sciences

All rights reserved.